NICE approval of adalimumab for moderate‐to‐severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?
Gespeichert in:
| Veröffentlicht in: | British journal of dermatology (1951) 2017-02, Vol.176 (2), p.281-282 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 282 |
|---|---|
| container_issue | 2 |
| container_start_page | 281 |
| container_title | British journal of dermatology (1951) |
| container_volume | 176 |
| creator | Ingram, J.R. Burton, T. |
| description | |
| doi_str_mv | 10.1111/bjd.15255 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1877814696</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1877814696</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3865-c97dd557707f18ee6ee64ad7ac57feac316c8101b79c6156b63a5c2daf6265873</originalsourceid><addsrcrecordid>eNqNkbtuFDEUhi0EIkug4AWQJRooNvFlbM_QINgECIqggdo6Y59JvJob9syidDwCRZ6QJ8GTDRRIkbAsHxefP-n3T8hTzo54Xsf11h9xJZS6R1ZcarUWXMr7ZMUYM2tWaXlAHqW0ZYxLpthDciBKURTMyBW5_nS2OaUwjnHYQUuHhoKHNnRzBzVthki7wWOECX_9-DkN-Ui4w4j0MvgIHvswhUTTPI5zhsIOXtHpEin2flEt1xovQt-H_uLGdtezBY0w4jwFl14_Jg8aaBM-uZ2H5Ou70y-bD-vzz-_PNm_O106WOaWrjPdKGcNMw0tEnXcB3oBTpkFwkmtXcsZrUznNla61BOWEh0YLrUojD8mLvTen_zZjmmwXksO2hR6HOVleGlPyQucf_A9UlKYSQmX0-T_odphjn4NYXglWFBXji_DlnnJxSCliY8cYOohXljO7tGpzq_am1cw-uzXOdYf-L_mnxgwc74HvocWru0327ceTvfI3LcOvaA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1920449016</pqid></control><display><type>article</type><title>NICE approval of adalimumab for moderate‐to‐severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ingram, J.R. ; Burton, T.</creator><creatorcontrib>Ingram, J.R. ; Burton, T.</creatorcontrib><identifier>ISSN: 0007-0963</identifier><identifier>EISSN: 1365-2133</identifier><identifier>DOI: 10.1111/bjd.15255</identifier><identifier>PMID: 28244073</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adalimumab ; Anti-Inflammatory Agents - therapeutic use ; Antibodies, Monoclonal - therapeutic use ; Hidradenitis Suppurativa - drug therapy ; Humans ; Monoclonal antibodies ; TNF inhibitors</subject><ispartof>British journal of dermatology (1951), 2017-02, Vol.176 (2), p.281-282</ispartof><rights>2017 British Association of Dermatologists</rights><rights>Copyright © 2017 British Association of Dermatologists</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3865-c97dd557707f18ee6ee64ad7ac57feac316c8101b79c6156b63a5c2daf6265873</citedby><cites>FETCH-LOGICAL-c3865-c97dd557707f18ee6ee64ad7ac57feac316c8101b79c6156b63a5c2daf6265873</cites><orcidid>0000-0002-5257-1142</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjd.15255$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjd.15255$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28244073$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ingram, J.R.</creatorcontrib><creatorcontrib>Burton, T.</creatorcontrib><title>NICE approval of adalimumab for moderate‐to‐severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?</title><title>British journal of dermatology (1951)</title><addtitle>Br J Dermatol</addtitle><subject>Adalimumab</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Hidradenitis Suppurativa - drug therapy</subject><subject>Humans</subject><subject>Monoclonal antibodies</subject><subject>TNF inhibitors</subject><issn>0007-0963</issn><issn>1365-2133</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkbtuFDEUhi0EIkug4AWQJRooNvFlbM_QINgECIqggdo6Y59JvJob9syidDwCRZ6QJ8GTDRRIkbAsHxefP-n3T8hTzo54Xsf11h9xJZS6R1ZcarUWXMr7ZMUYM2tWaXlAHqW0ZYxLpthDciBKURTMyBW5_nS2OaUwjnHYQUuHhoKHNnRzBzVthki7wWOECX_9-DkN-Ui4w4j0MvgIHvswhUTTPI5zhsIOXtHpEin2flEt1xovQt-H_uLGdtezBY0w4jwFl14_Jg8aaBM-uZ2H5Ou70y-bD-vzz-_PNm_O106WOaWrjPdKGcNMw0tEnXcB3oBTpkFwkmtXcsZrUznNla61BOWEh0YLrUojD8mLvTen_zZjmmwXksO2hR6HOVleGlPyQucf_A9UlKYSQmX0-T_odphjn4NYXglWFBXji_DlnnJxSCliY8cYOohXljO7tGpzq_am1cw-uzXOdYf-L_mnxgwc74HvocWru0327ceTvfI3LcOvaA</recordid><startdate>201702</startdate><enddate>201702</enddate><creator>Ingram, J.R.</creator><creator>Burton, T.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5257-1142</orcidid></search><sort><creationdate>201702</creationdate><title>NICE approval of adalimumab for moderate‐to‐severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?</title><author>Ingram, J.R. ; Burton, T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3865-c97dd557707f18ee6ee64ad7ac57feac316c8101b79c6156b63a5c2daf6265873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adalimumab</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Hidradenitis Suppurativa - drug therapy</topic><topic>Humans</topic><topic>Monoclonal antibodies</topic><topic>TNF inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ingram, J.R.</creatorcontrib><creatorcontrib>Burton, T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of dermatology (1951)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ingram, J.R.</au><au>Burton, T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NICE approval of adalimumab for moderate‐to‐severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?</atitle><jtitle>British journal of dermatology (1951)</jtitle><addtitle>Br J Dermatol</addtitle><date>2017-02</date><risdate>2017</risdate><volume>176</volume><issue>2</issue><spage>281</spage><epage>282</epage><pages>281-282</pages><issn>0007-0963</issn><eissn>1365-2133</eissn><cop>England</cop><pub>Oxford University Press</pub><pmid>28244073</pmid><doi>10.1111/bjd.15255</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-5257-1142</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0963 |
| ispartof | British journal of dermatology (1951), 2017-02, Vol.176 (2), p.281-282 |
| issn | 0007-0963 1365-2133 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1877814696 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adalimumab Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal - therapeutic use Hidradenitis Suppurativa - drug therapy Humans Monoclonal antibodies TNF inhibitors |
| title | NICE approval of adalimumab for moderate‐to‐severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T03%3A37%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NICE%20approval%20of%20adalimumab%20for%20moderate%E2%80%90to%E2%80%90severe%20hidradenitis%20suppurativa:%20the%20end%20of%20the%20beginning%20for%20hidradenitis%20suppurativa%20therapeutics?&rft.jtitle=British%20journal%20of%20dermatology%20(1951)&rft.au=Ingram,%20J.R.&rft.date=2017-02&rft.volume=176&rft.issue=2&rft.spage=281&rft.epage=282&rft.pages=281-282&rft.issn=0007-0963&rft.eissn=1365-2133&rft_id=info:doi/10.1111/bjd.15255&rft_dat=%3Cproquest_cross%3E1877814696%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1920449016&rft_id=info:pmid/28244073&rfr_iscdi=true |